Aptevo Therapeutics Shares Surge Amid Clinical Milestone
By ATTN Desk · Editorial oversight: Sean Han
Aptevo Therapeutics Inc (NASDAQ: APVO)
1. Introduction
Aptevo Therapeutics Inc. is a clinical-stage biotechnology company headquartered in Seattle, Washington. Founded in 2016, Aptevo utilizes its proprietary ADAPTIR™ and ADAPTIR-FLEX™ platforms to develop bispecific immunotherapies for the treatment of blood and solid tumor malignancies.
2. Corporate Structure
- Headquarters: 2401 4th Avenue, Suite 1050, Seattle, WA 98121
- Founded: 2016
- Employees: 51–200 (LinkedIn)
- Key Platforms:
- ADAPTIR™ (redirected T-cell cytotoxicity, co-stimulation)
- ADAPTIR-FLEX™ (modular multispecific design)
- Leadership:
- Marvin White, President & CEO
- Investor Relations: Miriam Weber Miller
3. Recent Developments and News
May 21, 2025 – Market Performance
| Metric | Value |
|---|---|
| Share Price | $0.4550 |
| Daily Change | +46.82% |
| Volume | 56,880,778 |
| Exchange | NASDAQ (APVO) |
SEC Filings
- Form 10-Q (May 15, 2025): Quarterly report for the period ended March 31, 2025.
- Form 8-K (May 15, 2025): Current report covering material events.
- Form S-1 (May 13, 2025): Registration of securities under the Securities Act of 1933.
Corporate Communications
- May 2025: Marvin White appeared on Bloomberg TV’s Small Stocks, Big Money to discuss clinical progress and long-term growth.
- January 2025: Peter Pavlik, PhD, chaired a session on “Bi and Multispecific Biologics” at the Cambridge Healthcare Institute’s PepTalk conference.
- Clinical Update: In the RAINIER Phase 1b/2 trial of mipletamig (CD3 × CD123 bispecific), the first patient dosed achieved a 90% reduction in leukemic blasts within 30 days.
4. Financial and Strategic Analysis
Key Financial Metrics (TTM, per Yahoo Finance)
- Market Cap: $2.38 million
- Enterprise Value: $4.66 million
- Beta (5Y Monthly): 6.06
- Net Income (ttm): –$24.13 million
- Return on Assets: –76.06%
- Return on Equity: –284.28%
- Total Cash (mrq): $8.71 million
- Total Debt/Equity (mrq): 113.52%
- Levered Free Cash Flow (ttm): –$15.52 million
Strategic Initiatives
- Pipeline Advancement: Two clinical candidates and three preclinical bispecifics targeting oncology and autoimmune indications.
- Capital Formation: The S-1 filing indicates plans to raise additional funds for R&D and operations.
- Partnerships & Presentations: Engagements at industry conferences and media appearances to emphasize platform capabilities and trial data.
5. Market Position and Industry Context
- Therapeutic Focus: Bispecific immuno-oncology agents designed to engage multiple immune pathways.
- Market Growth: The bispecific antibody market is projected to grow approximately 44% through 2030 (Grand View Research).
- Competitive Landscape: Other clinical-stage biotech firms are leveraging bispecific platforms; Aptevo differentiates via modular ADAPTIR technology.
- Stock Volatility: The 52-week trading range has been between $0.2430 and $32.93, reflecting the high beta and speculative nature of the shares.
TL;DR
- On May 21, 2025, APVO shares rose 46.82% to $0.4550 on high trading volume (56.9 million shares).
- The company filed its Q1 2025 10-Q and 8-K on May 15, followed by an S-1 on May 13, 2025.
- Clinical milestone: The first patient in the RAINIER Phase 1b/2 trial of mipletamig experienced a 90% reduction in leukemic blasts within 30 days.
- Financials (ttm): net loss $24.13 million, cash $8.71 million, debt/equity 113.52%; market cap $2.38 million.
- Aptevo is focused on leveraging its ADAPTIR™ platforms and upcoming capital raise to advance its bispecific pipeline in a market anticipated to grow through 2030.